Exelixis EXEL Accrued Compensation
Accrued Compensation at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:AccruedEmployeeBenefitsCurrent.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's accrued compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's accrued compensation?
- Exelixis (EXEL) reported accrued compensation of $87.51M in Q1 2026.
- How has Exelixis's accrued compensation changed year-over-year?
- Exelixis's accrued compensation decreased by 2.5% year-over-year, from $89.75M to $87.51M.
- What is the long-term trend for Exelixis's accrued compensation?
- Over 5 years (2020 to 2025), Exelixis's accrued compensation has grown at a 14.8% compound annual growth rate (CAGR), from $51.19M to $102.22M.
- What does accrued compensation mean?
- The amount of money the company owes to employees for work performed but not yet paid.
- How do you interpret accrued compensation?
- Increases often correlate with headcount growth or the accrual of performance-based bonuses, while decreases may signal the payout of annual incentives.
- How does accrued compensation compare across companies?
- Common in all companies; biopharma firms often see fluctuations based on the timing of annual bonus cycles and R&D staffing levels.